首页> 美国卫生研究院文献>Cancer Medicine >Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors

【2h】

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors

机译：未能通过酪氨酸激酶抑制剂治疗的BCR-ABL突变的慢性粒细胞白血病患者的发生率和结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeTo assess the incidence of BCR‐ABL kinase domain (KD) mutation detection and its prognostic significance in chronic phase chronic myeloid leukemia (CP‐CML) patients treated with tyrosine kinase inhibitors (TKIs).

机译：目的评估使用酪氨酸激酶抑制剂（TKIs）治疗的慢性慢性粒细胞白血病（CP-CML）患者中BCR-ABL激酶结构域（KD）突变检测的发生率及其预后意义。

著录项

期刊名称 Cancer Medicine
作者
Gabriel Etienne; Stéphanie Dulucq; Françoise Huguet; Anna Schmitt; Axelle Lascaux; Sandrine Hayette; Marie‐Pierre Fort; Pierre Sujobert; Fontanet Bijou; Stéphane Morisset; Suzanne Tavitian; Audrey Bidet; Beatrice Turcq; Fanny Robbesyn; Claudine Chollet; Francis Belloc; Françoise Durrieu; François‐Xavier Mahon; Franck E. Nicolini;
展开▼
作者单位

展开▼
年(卷),期 2019(8),11
年度 2019
页码 5173–5182
总页数 10
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
BCR-ABL kinase domain mutation chronic myeloid leukemia tyrosine kinase inhibitors;

机译：BCR-ABL激酶结构域突变;慢性粒细胞白血病;酪氨酸激酶抑制剂;

相似文献

外文文献
中文文献
专利

1. Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors [J] . Gabriel Etienne, Stéphanie Dulucq, Fran?oise Huguet, Cancer Medicine . 2019,第11期

机译：BCR-ABL突变的慢性骨髓白血病未能酪氨酸激酶抑制剂的慢性骨髓性白血病患者的发病率和结果
2. The impact of BCR‐ABL1 BCR‐ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia [J] . Ercaliskan Abdulkadir, Eskazan A. Emre Cancer: A Journal of the American Cancer Society . 2018,第19期

机译：BCR-ABL1 BCR-ABL1转录型对慢性骨髓白血病患者酪氨酸激酶抑制剂反应和结果的影响
3. Quantifying mutated and unmutated BCR-ABL transcripts confirms suitability of direct sequencing sensitivity in mutation analysis of patients with chronic myeloid leukemia with secondary resistance to tyrosine kinase inhibitors, regardless of ratio values. [J] . Santamaria I, Payer AR, Pitiot AS, Leukemia and lymphoma . 2010,第2期

机译：对突变和未突变的BCR-ABL转录本进行定量，证实了直接测序敏感性适用于患有慢性髓样白血病且对酪氨酸激酶抑制剂具有二次耐药性的患者的突变分析，无论其比率值如何。
4. Novel Inhibitors of T315I Mutant BCR-ABL1 Tyrosine Kinase for Chronic Myeloid Leukemia Disease Through Fragment-Based Drug Design [C] . Satya Anindita, Atika Marnolia, Hersal Hermana Putra, International symposium on bioinformatics research and applications . 2018

机译：T315I突变BCR-ABL1酪氨酸激酶的新型抑制剂通过基于片段的药物设计治疗慢性粒细胞白血病
5. New strategies for targeted chronic myeloid leukemia therapy: Disrupting BCR-ABL1 dimerization and secondary leukemia-specific pathways [D] . Woessner, David W. 2013

机译：针对性慢性粒细胞白血病治疗的新策略：破坏BCR-ABL1二聚化和继发性白血病特异性途径
6. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10 of BCR-ABL/ABL ratio at 3 months [O] . Luis-Felipe Casado, José-Valentín García-Gutiérrez, Isabel Massagué, 2015

机译：改用第二代酪氨酸激酶抑制剂可改善一线伊马替尼治疗的慢性粒细胞白血病患者的反应和预后在3个月时其BCR-ABL / ABL比率超过10％
7. Assessment ofBCR-ABL1Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors [O] . David Marin, Amr R. Ibrahim, Claire Lucas, 2012

机译：3个月的BCCR-ABL1TRANScript水平评估是用酪氨酸激酶抑制剂治疗慢性骨髓白血病患者预测结果的唯一要求

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors

摘要

著录项

相似文献

相关主题

期刊订阅